Emanuela Amici
Biographic Data
| ID | 7681202 |
|---|---|
| NAME | Emanuela Amici |
| GIVEN NAMES | Emanuela |
| FAMILY NAME | Amici |
| SIGNATURE | AMICI E |
| ORCID | 0009-0003-5347-7160 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Brexpiprazole in patients with schizophrenia with or without substance use disorder
Treatment with brexpiprazole for 6 months improved psychotic symptoms in patients with schizophrenia, independently from whether they belonged to the SUD or the non-SUD group; hence, SUD comorbidity did not confer treatment resistance to brexpiprazole. Furthermore, in the SUD group, we observed reduced substance craving
Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once month…
No prominent works on this page.
Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in young people with schizophrenia at their first psychotic episode (FEP). Objective: Our study aimed to assess the effect of LAI aripiprazole once month…
Brexpiprazole in patients with schizophrenia with or without substance use disorder
Treatment with brexpiprazole for 6 months improved psychotic symptoms in patients with schizophrenia, independently from whether they belonged to the SUD or the non-SUD group; hence, SUD comorbidity did not confer treatment resistance to brexpiprazole. Furthermore, in the SUD group, we observed reduced substance craving
Internal Medicine (2 works) · Medicine (2 works) · Positive and Negative Syndrome Scale (2 works) · Psychiatry (2 works) · Psychology (2 works) · Psychosis (2 works) · Schizophrenia (object-oriented programming (2 works) · Schizophrenia research and treatment (2 works) · Addiction (1 work) · Agonist (1 work)